Wada Seiki, Kamiya Sadahiro, Fukawa Takeshi
Josai International University, Department of Clinical Science, Faculty of Pharmaceutical Sciences.
Clin Calcium. 2006 Nov;16(11):1871-77.
Inhaled glucocorticoids are the standard of therapy in asthma and are commonly prescribed for chronic obstructive pulmonary disease. Accumulating evidence suggests that the effect of inhaled glucocorticoids on bone is not small, especially in patients taking moderate or high doses for long periods of time. The risk of adverse events is likely to differ between inhaled glucocorticoids. Inhaled glucocorticoids should be used widely, since they reduce the need of oral corticosteroids and improve respiratory function, but that they need to be managed carefully to minimize the risk of fracture with long-term use. This article described the effects of inhaled glucocorticoids on bone and fracture risk.
吸入性糖皮质激素是哮喘治疗的标准药物，常用于慢性阻塞性肺疾病的治疗。越来越多的证据表明，吸入性糖皮质激素对骨骼的影响不容小觑，尤其是长期服用中高剂量药物的患者。不同吸入性糖皮质激素导致不良事件的风险可能存在差异。吸入性糖皮质激素应广泛使用，因为它们可减少口服糖皮质激素的使用需求并改善呼吸功能，但需要谨慎管理，以将长期使用导致骨折的风险降至最低。本文描述了吸入性糖皮质激素对骨骼及骨折风险的影响。
